76 related articles for article (PubMed ID: 21351569)
1. [Synthesis and structure-activity relationship of 13-hexylberberine analogues as CD36 antagonists].
Li YH; Wang L; Hong B; Xu YN; Si SY; Jiang JD; Song DQ
Yao Xue Xue Bao; 2010 Sep; 45(9):1128-33. PubMed ID: 21351569
[TBL] [Abstract][Full Text] [Related]
2. Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model.
Xu Y; Wang J; Bao Y; Jiang W; Zuo L; Song D; Hong B; Si S
Anal Biochem; 2010 May; 400(2):207-12. PubMed ID: 20152792
[TBL] [Abstract][Full Text] [Related]
3. Discovery of antagonists for human scavenger receptor CD36 via an ELISA-like high-throughput screening assay.
Wang L; Bao Y; Yang Y; Wu Y; Chen X; Si S; Hong B
J Biomol Screen; 2010 Mar; 15(3):239-50. PubMed ID: 20150587
[TBL] [Abstract][Full Text] [Related]
4. [The in vitro anti-atherosclerotic activity of compound IMB-1680].
Feng TT; Li YZ; Li N; Liu C; Wang X; Xu YN; Si SY
Yao Xue Xue Bao; 2014 May; 49(5):602-7. PubMed ID: 25151728
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationship of N-(2-arylethyl) isoquinoline derivatives as human scavenger receptor CD36 antagonists.
Wang YX; Wang L; Xu YN; Li YH; Jiang JD; Si SY; Li YB; Ren G; Shan YQ; Hong B; Song DQ
Eur J Med Chem; 2011 Apr; 46(4):1066-73. PubMed ID: 21295889
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor.
Wang YX; Wang YP; Zhang H; Kong WJ; Li YH; Liu F; Gao RM; Liu T; Jiang JD; Song DQ
Bioorg Med Chem Lett; 2009 Nov; 19(21):6004-8. PubMed ID: 19800225
[TBL] [Abstract][Full Text] [Related]
7. Human scavenger protein AIM increases foam cell formation and CD36-mediated oxLDL uptake.
Amézaga N; Sanjurjo L; Julve J; Aran G; Pérez-Cabezas B; Bastos-Amador P; Armengol C; Vilella R; Escolà-Gil JC; Blanco-Vaca F; Borràs FE; Valledor AF; Sarrias MR
J Leukoc Biol; 2014 Mar; 95(3):509-20. PubMed ID: 24295828
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators.
Yang P; Song DQ; Li YH; Kong WJ; Wang YX; Gao LM; Liu SY; Cao RQ; Jiang JD
Bioorg Med Chem Lett; 2008 Aug; 18(16):4675-7. PubMed ID: 18644725
[TBL] [Abstract][Full Text] [Related]
9. CD36 and macrophages in atherosclerosis.
Collot-Teixeira S; Martin J; McDermott-Roe C; Poston R; McGregor JL
Cardiovasc Res; 2007 Aug; 75(3):468-77. PubMed ID: 17442283
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation.
Wang YX; Kong WJ; Li YH; Tang S; Li Z; Li YB; Shan YQ; Bi CW; Jiang JD; Song DQ
Bioorg Med Chem; 2012 Nov; 20(22):6552-8. PubMed ID: 23058107
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Evolution of Berberine Derivatives as a New Class of Antiviral Agents against Enterovirus 71 through the MEK/ERK Pathway and Autophagy.
Wang YX; Yang L; Wang HQ; Zhao XQ; Liu T; Li YH; Zeng QX; Li YH; Song DQ
Molecules; 2018 Aug; 23(8):. PubMed ID: 30127288
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of 13-(substituted benzyl) berberine and berberrubine derivatives as antifungal agents.
Park KD; Lee JH; Kim SH; Kang TH; Moon JS; Kim SU
Bioorg Med Chem Lett; 2006 Aug; 16(15):3913-6. PubMed ID: 16730982
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of berberine derivatives as a new class of broad-spectrum antiviral agents against Coxsackievirus B.
Zeng QX; Wang HQ; Wei W; Guo TT; Yu L; Wang YX; Li YH; Song DQ
Bioorg Chem; 2020 Jan; 95():103490. PubMed ID: 31855821
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of GHRP-6 azapeptide ligands of the CD36 scavenger receptor by solid-phase submonomer azapeptide synthesis.
Sabatino D; Proulx C; Pohankova P; Ong H; Lubell WD
J Am Chem Soc; 2011 Aug; 133(32):12493-506. PubMed ID: 21692501
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and molecular modeling of novel triazole-containing berberine derivatives as acetylcholinesterase and β-amyloid aggregation inhibitors.
Shi A; Huang L; Lu C; He F; Li X
Bioorg Med Chem; 2011 Apr; 19(7):2298-305. PubMed ID: 21397508
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of some 13-alkyl substituted protoberberinium salts.
Iwasa K; Kamigauchi M; Sugiura M; Nanba H
Planta Med; 1997 Jun; 63(3):196-8. PubMed ID: 9225598
[TBL] [Abstract][Full Text] [Related]
17. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions.
Chen Y; Li Y; Wang Y; Wen Y; Sun C
Metabolism; 2009 Dec; 58(12):1694-702. PubMed ID: 19767038
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression.
Tang FT; Cao Y; Wang TQ; Wang LJ; Guo J; Zhou XS; Xu SW; Liu WH; Liu PQ; Huang HQ
Eur J Pharmacol; 2011 Jan; 650(1):275-84. PubMed ID: 20854809
[TBL] [Abstract][Full Text] [Related]
19. Syntheses and Structure-Activity Relationships in Growth Inhibition Activity against Human Cancer Cell Lines of 12 Substituted Berberine Derivatives.
Wang B; Deng AJ; Li ZH; Wang N; Qin HL
Molecules; 2020 Apr; 25(8):. PubMed ID: 32325679
[TBL] [Abstract][Full Text] [Related]
20. PKCδ signalling regulates SR-A and CD36 expression and foam cell formation.
Lin CS; Lin FY; Ho LJ; Tsai CS; Cheng SM; Wu WL; Huang CY; Lian CH; Yang SP; Lai JH
Cardiovasc Res; 2012 Aug; 95(3):346-55. PubMed ID: 22687273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
